PFIZER INC Other Asset Impairment Charges
PFIZER INC (PFE) reported Other Asset Impairment Charges of $48.00 million for the 9-month period ending 2019-09-29, per its 10-Q filed 2020-11-05.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OtherAssetImpairmentCharges · last filed 2020-11-05
- PFIZER INC other asset impairment charges for the quarter ending 2019-09-29 was $28.00M.
- PFIZER INC other asset impairment charges for the quarter ending 2019-06-30 was $0.00.
- PFIZER INC other asset impairment charges for the quarter ending 2019-03-31 was $20.00M.
- PFIZER INC other asset impairment charges for fiscal 2018 was $13.00M.
| Period end | Other Asset Impairment Charges 3 month | Other Asset Impairment Charges 6 month | Other Asset Impairment Charges 9 month | Other Asset Impairment Charges 12 month |
|---|---|---|---|---|
| 2019-09-29 | $28.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $28.00M derived: sum of 2 quarters · filed 2020-11-05 | $48.00M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $20.00M 10-Q · filed 2020-08-06 | ||
| 2019-03-31 | $20.00M 10-Q · filed 2020-05-07 | |||
| 2018-12-31 | $13.00M 10-K · filed 2019-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |